320 related articles for article (PubMed ID: 23192697)
21. Elevated serum levels of kynurenine pathway metabolites in patients with Behçet disease.
Eryavuz Onmaz D; Tezcan D; Abusoglu S; Sivrikaya A; Kuzu M; Yerlikaya FH; Yilmaz S; Unlu A
Amino Acids; 2022 Jun; 54(6):877-887. PubMed ID: 35604497
[TBL] [Abstract][Full Text] [Related]
22. A validated liquid chromatography-high resolution-tandem mass spectrometry method for the simultaneous quantitation of tryptophan, kynurenine, kynurenic acid, and quinolinic acid in human plasma.
Arnhard K; Pitterl F; Sperner-Unterweger B; Fuchs D; Koal T; Oberacher H
Electrophoresis; 2018 May; 39(9-10):1171-1180. PubMed ID: 29327354
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous measurement of kynurenine metabolites and explorative metabolomics using liquid chromatography-mass spectrometry: A novel accurate method applied to serum and plasma samples from a large healthy cohort.
Eggertsen PP; Hansen J; Andersen ML; Nielsen JF; Olsen RKJ; Palmfeldt J
J Pharm Biomed Anal; 2023 Apr; 227():115304. PubMed ID: 36827735
[TBL] [Abstract][Full Text] [Related]
24. Low Serum Tryptophan Levels as an Indicator of Global Cognitive Performance in Nondemented Women over 50 Years of Age.
Ramos-Chávez LA; Roldán-Roldán G; García-Juárez B; González-Esquivel D; Pérez de la Cruz G; Pineda B; Ramírez-Ortega D; García Muñoz I; Jiménez Herrera B; Ríos C; Gómez-Manzo S; Marcial-Quino J; Sánchez Chapul L; Carrillo Mora P; Pérez de la Cruz V
Oxid Med Cell Longev; 2018; 2018():8604718. PubMed ID: 30584466
[TBL] [Abstract][Full Text] [Related]
25. Kynurenine Pathway Metabolites in Alzheimer's Disease.
Giil LM; Midttun Ø; Refsum H; Ulvik A; Advani R; Smith AD; Ueland PM
J Alzheimers Dis; 2017; 60(2):495-504. PubMed ID: 28869479
[TBL] [Abstract][Full Text] [Related]
26. Role of d-amino acid oxidase in the production of kynurenine pathway metabolites from d-tryptophan in mice.
Notarangelo FM; Wang XD; Horning KJ; Schwarcz R
J Neurochem; 2016 Feb; 136(4):804-814. PubMed ID: 26661897
[TBL] [Abstract][Full Text] [Related]
27. Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition.
Zavitsanou K; Lim CK; Purves-Tyson T; Karl T; Kassiou M; Banister SD; Guillemin GJ; Weickert CS
Brain Behav Immun; 2014 Oct; 41():173-81. PubMed ID: 24878170
[TBL] [Abstract][Full Text] [Related]
28. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
29. Altered kynurenine pathway metabolites in serum of chronic migraine patients.
Curto M; Lionetto L; Negro A; Capi M; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
J Headache Pain; 2015; 17():47. PubMed ID: 27130315
[TBL] [Abstract][Full Text] [Related]
30. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
31. Drosophila eye color mutants as therapeutic tools for Huntington disease.
Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
[TBL] [Abstract][Full Text] [Related]
32. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
33. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
34. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
[TBL] [Abstract][Full Text] [Related]
35. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
Chatterjee P; Zetterberg H; Goozee K; Lim CK; Jacobs KR; Ashton NJ; Hye A; Pedrini S; Sohrabi HR; Shah T; Asih PR; Dave P; Shen K; Taddei K; Lovejoy DB; Guillemin GJ; Blennow K; Martins RN
J Neuroinflammation; 2019 Oct; 16(1):186. PubMed ID: 31601232
[TBL] [Abstract][Full Text] [Related]
36. Central levels of tryptophan metabolites in subjects with bipolar disorder.
Trepci A; Sellgren CM; Pålsson E; Brundin L; Khanlarkhani N; Schwieler L; Landén M; Erhardt S
Eur Neuropsychopharmacol; 2021 Feb; 43():52-62. PubMed ID: 33339712
[TBL] [Abstract][Full Text] [Related]
37. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk A; Urbanska EM
CNS Neurosci Ther; 2022 Jan; 28(1):19-35. PubMed ID: 34862742
[TBL] [Abstract][Full Text] [Related]
38. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.
Guloksuz S; Arts B; Walter S; Drukker M; Rodriguez L; Myint AM; Schwarz MJ; Ponds R; van Os J; Kenis G; Rutten BP
Brain Behav Immun; 2015 Aug; 48():48-52. PubMed ID: 25765557
[TBL] [Abstract][Full Text] [Related]
39. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
[TBL] [Abstract][Full Text] [Related]
40. Kynurenine Pathway in Autism Spectrum Disorders in Children.
Bryn V; Verkerk R; Skjeldal OH; Saugstad OD; Ormstad H
Neuropsychobiology; 2017; 76(2):82-88. PubMed ID: 29694960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
